O-RAN Alliance Conducts First Global Plugfest to Foster Adoption of Open and Interoperable 5G Radio Access Networks
19.12.2019 13:57:00 EET | Business Wire | Press release
The O-RAN Alliance successfully conducted its first worldwide plugfest and proof of concept to demonstrate the functionality as well as the multi-vendor interoperability of network equipment that complies with the recently published O1, A1, and Open Fronthaul interface specifications.
“O-RAN’s first global plugfest showcases the power of the community to document and develop truly open interface specifications with the potential to accelerate new 5G advanced services that will be multi-operator, multi-vendor, and create opportunities for the entire ecosystem,” said Andre Fuetsch, Chairman of the O-RAN Alliance and Chief Technology Officer of AT&T. “These live demonstrations represent yet another step toward the realization of O-RAN compliant 5G RAN solutions that should soon become part of the product offerings of both mainstream and niche vendors.”
ASIA
Hosted by China Mobile, the plugfest Asian Session was held in the China Mobile International Information Port, an Open Test and Integration Center, with physical attendance well over 200 attendees from over 70 companies, plus on-line attendance of over 70 participants. Representatives from global operators including British Telecom, China Telecom, China Unicom, NTT DOCOMO, Orange, Reliance Jio, Telecom Italia Mobile and an operator from North America have actively participated in this event. The plugfest tested and integrated multi-vendor solutions that comply with the O-RAN Open Fronthaul interface and exercised decoupling different hardware technologies from the RAN software:
- Cloud-based small cell running on virtualization technology was demonstrated by CertusNet, Lenovo, ChengDu NTS and Inventec. It features a VM-based O-CU and containerized O-DU cohosted on the same x86 processor plus accelerator platform.
- Multi-vendor interoperability with 5G commercial products was demonstrated by NTT DOCOMO with Fujitsu and NEC.
- A low power configuration of cloud base station running on Yocto OS and container technology was demonstrated by Altran, ArrayComm, WindRiver, Baicells and CIG. It features the open architecture baseband signal processing based on ARM processor plus accelerator computing platform.
- Soft base station with O-RAN compliant open fronthaul interface, but without virtualization, was demonstrated by Radisys, Foxconn (Taiwan), QCT and Intel. It leverages open source software including the O-RAN Open Source Community’s OFH Lib, and BBDev based Accelerator Abstraction Layer SDK API.
- The interworking of the O-RAN open fronthaul interface was demonstrated on technology provided by FHK (Shenzen) and Viavi, which performs comprehensive tests based on the test specification by O-RAN with O-RU and UE emulator in a multiple-UE test environment.
The plugfest held in the NTT DOCOMO R&D Center presented multi-vendor interoperability between CU/O-DU and O-RU using the O-RAN Open Fronthaul interface and multi-vendor interoperability between eNB and gNB using the O-RAN X2 interface. The functionality has been successfully demonstrated by NTT DOCOMO, Fujitsu, NEC, and Nokia. NTT DOCOMO has already started 5G pre-commercial service with the presented products. An Open Test and Integration Center is planned to be established in Japan.
NORTH AMERICA
The plugfest and proof-of-concept conducted within an Open Test and Integration Center candidate in North America, 5G COSMOS, which consists of vendor and university labs in the NYC metro area, was hosted by AT&T and focused primarily on the validation of the O1 and A1 interfaces:
- Physical Network Function (PNF) Plug and Play, a 3GPP-aligned O1 use case that provides a means for service providers to collaborate with equipment vendors to have PNFs discovered by Service Management Orchestration (SMO) via a PNF registration handler, was demonstrated by Nokia, CommScope and Ericsson. Remote SMO functions were also demonstrated with connections to labs in France and Germany.
- Bulk Performance Management Data Collection was demonstrated by Ericsson and Nokia.
- O1 interface functionality for Configuration, Performance, and Fault Management of multi-vendor equipment via a vendor-agnostic SMO was demonstrated by Altiostar, CommScope, and Samsung.
- A1 interface functionality to optimize PCI/RSI for a large-scale RAN simulator using a closed loop automation framework was demonstrated by IBM, Tech Mahindra, Wipro and highstreet technologies.
- Convergence of the Open Fronthaul Management Plane specification with O1 interface was demonstrated by Samsung.
“The O-RAN Alliance has been continuously expanding its influence in the industry since its inception. It is really amazing to see such a symbolic milestone achieved just 10 months since its release of the first specification in MWC Barcelona this year,” said Zhengmao Li, EVP of China Mobile. “The successful holding of the plugfest event globally with deep contribution from over 30 partners represents a consolidated step towards a full disaggregated O-RAN compliant 5G network.”
Dr. Hiroshi Nakamura, EVP and CTO, NTT DOCOMO commented, "We believe wide adoption of O-RAN compliant products will enable more agile, flexible and cost-effective network construction, and welcome the testing and integration efforts of O-RAN standards that are being carried out across the globe. NTT DOCOMO will continue to lead O-RAN Alliance activities and expand its 5G network, and will accelerate the co-creation of 5G services and markets with vertical industry partners."
O-RAN Industry Briefing at MWC 2020
For a comprehensive update on O-RAN activities, including significant developments in Europe, the O-RAN community will come together for the O-RAN Industry Briefing event at MWC Barcelona 2020. Representatives from O-RAN operator and vendor member organizations will discuss and share views on the important steps towards realizing O-RAN compliant commercial solutions. O-RAN Alliance is looking forward to meeting you on Feb 25, 2020, 9:30-10:30 am at the Deutsche Telekom Booth, Hall 3, Booth 3M31.
About O-RAN Alliance
O-RAN Alliance is a world-wide community of more than 130 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, O-RAN Alliance’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, O-RAN Alliance publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005289/en/
Contact information
O-RAN Alliance PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN Alliance e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
